Open AccessSwitching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV
Author(s) -
Huan Xia,
Xiaojie Huang,
Yue Hu,
Lina Gao,
Yue Wu,
Hao Wu,
Zhongfang Yan,
Ping Ma
Publication year - 2021
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001824
Subject(s) - efavirenz , elvitegravir , tenofovir alafenamide , medicine , cobicistat , emtricitabine , regimen , alprazolam , prospective cohort study , tolerability , adverse effect , anxiety , viral load , human immunodeficiency virus (hiv) , immunology , psychiatry , antiretroviral therapy
Central nervous system (CNS) symptoms after efavirenz (EFV) treatment in people living with human immunodeficiency virus (HIV) could persist and impact their quality of life. We assessed the impact of EFV-based regimen replacement with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), which is considered an alternative option for subjects who do not tolerate EFV. Most specifically, we assessed the safety and the efficacy of E/C/F/TAF and its effects on the participants' neuropsychiatric toxicity symptoms in a real-life setting.